DexCom (NASDAQ:DXCM) Stock Unloaded Rep. Kevin Hern

Representative Kevin Hern (R-Oklahoma) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $50,001 and $100,000 in DexCom stock on December 31st. The trade occurred in the Representative's "HERN FAMILY REVOCABLE TRUST > BROKERAGE INVESTMENT ACCOUNT" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Intel NASDAQ: INTC on 12/31/2024.
• Sold $250,001 - $500,000 in shares of Devon Energy NYSE: DVN on 12/31/2024.
• Sold $15,001 - $50,000 in shares of Estée Lauder Companies NYSE: EL on 12/31/2024.
• Sold $100,001 - $250,000 in shares of Johnson & Johnson NYSE: JNJ on 12/31/2024.
• Sold $50,001 - $100,000 in shares of AGCO NYSE: AGCO on 12/31/2024.
• Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 12/12/2024.
• Purchased $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 12/10/2024.
• Purchased $100,001 - $250,000 in shares of McDonald's NYSE: MCD on 10/29/2024.

DexCom Stock Performance

Shares of DexCom stock traded down $0.46 during trading hours on Friday, reaching $84.38. 5,134,065 shares of the stock traded hands, compared to its average volume of 3,952,632. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market capitalization of $32.96 billion, a price-to-earnings ratio of 50.53, a P/E/G ratio of 2.00 and a beta of 1.12. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a 50 day moving average price of $78.17 and a 200 day moving average price of $78.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Thoroughbred Financial Services LLC purchased a new position in shares of DexCom in the second quarter worth $211,000. Envestnet Asset Management Inc. lifted its stake in DexCom by 0.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 599,303 shares of the medical device company's stock worth $67,949,000 after purchasing an additional 3,356 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of DexCom by 41.3% during the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company's stock valued at $104,282,000 after purchasing an additional 268,802 shares in the last quarter. Finally, GDS Wealth Management increased its holdings in shares of DexCom by 41.7% in the second quarter. GDS Wealth Management now owns 54,770 shares of the medical device company's stock worth $6,210,000 after purchasing an additional 16,128 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company's stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. StockNews.com lowered shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. JPMorgan Chase & Co. upped their price objective on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, October 25th. Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Finally, Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $99.29.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2025. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2024 election. Before running for Congress, Hern was a McDonald's franchisee and served on the McDonald's National Leadership Team. Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.